Skip to main content

Table 2 Baseline Characteristics by Subset

From: A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps

 

Subset 1

(N = 44)

Subset 2

(N = 129)

P Value

Demographics

Gender Female n (%)

26 (59.1)

103 (79.8)

0.009

Age (years) mean (±SD)

50.0 (±6.1)

59.7 (±10.5)

< 0.001

Weight (kg) mean (±SD)

75.6 (±16.1)

74.7 (±12.4)

0.638

Height (cm) mean (±SD)

171.4 (±12.5)

166.1 (±7.7)

0.001

BMI (kg/m2) mean (±SD)

25.5 (±3.4)

27.1 (±4.4)

0.108

Physiological parameters

Systolic blood pressure (mmHg) mean (±SD)

134.2 (±11.4)

127.7 (±10.2)

< 0.001

Diastolic blood pressure (mmHg) mean (±SD)

83.4 (±5.2)

78.2 (±6.5)

< 0.001

Heart rate (beats/min) mean (±SD)

70.6 (±5.0)

71.8 (±6.7)

0.429

Baseline efficacy parameters

NLC frequency (num/week) mean (±SD)

3.9 (±0.8)

6.6 (±7.9)

0.003

NLC duration (sec/week) mean (±SD)

48.7 (±12.9)

326.1 (±244.5)

< 0.001

NLC pain (mean VAS/week) mean (±SD)

6.7 (±0.9)

6.6 (±1.6)

0.686

Sleep quality (mean cumulative score/week) mean (±SD)

13.0 (±2.9)

12.7 (±3.7)

0.627

  1. BMI body mass index, NLC nocturnal leg cramps, SD standard deviation, VAS visual analogue scale